Barbara J. Comly, EVP, General Counsel and Corporate Secretary of Miami International Holdings, Inc., filed a Form 4 on November 4, 2026, disclosing option exercises and open-market sales of common stock on November 2 and November 4, 2026, executed under a pre-established Rule 10b5-1 …
Barbara J. Comly, an officer of Miami International Holdings Inc, filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 150,466 shares of common stock via exercise of stock options, with an aggregate market value of $5,094,778.76.
Director Anthony M. Eisen filed a Form 144 notice of proposed sale of 35,000 shares of Block, Inc. common stock on November 4, 2026, listing Morgan Stanley Smith Barney LLC Executive Financial Services as the executing broker.
ZipRecruiter Inc. officer Boris Shimanovsky filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 30,000 shares of ZipRecruiter common stock through Morgan Stanley Smith Barney LLC.
F5, Inc. officer Michael Montoya filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 1,297 shares of F5 common stock on NASDAQ under a Rule 10b5-1 plan.
F5, Inc. officer Thomas Fountain filed a Form 144 notice of proposed sale of 9,387 shares of F5 common stock on November 4, 2026, pursuant to Rule 144 under the Securities Act of 1933.
A Form 144 notice of proposed sale was filed on November 4, 2026, by Spenser Skates on behalf of Anne L. Skates, spouse of Spenser J. Skates, an Officer and Director of Amplitude, Inc., covering 901 Class A shares of Amplitude with an aggregate …
Andrew S. Greiff, an officer of Ryerson Holding Corp, filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 3,000 shares of Ryerson common stock on the New York Stock Exchange through Fidelity Brokerage Services LLC.
Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc, filed a Form 4 on November 4, 2026, disclosing a stock option exercise and the sale of 5,000 shares of common stock on November 2, 2026, under a Rule 10b5-1 trading plan.
Director Jason Aryeh filed a Form 144 notice of proposed sale on November 4, 2026, disclosing plans to sell 282 shares of Ligand Pharmaceuticals Inc. Class B common stock through Wells Fargo Clearing Services.